| |
|
岡 慎一 |
国立国際医療研究センター
エイズ治療・研究開発センター長
|
| HIV感染症、臨床ウイルス学、多施設共同臨床試験 |
| CD4+ count-guided interruption of antiretroviral treatment.The Smart Study Group (Oka S as a principal investigator of the Sydney Regional Coordinating Center). N Engl J Med 355: 2283-2296, 2006 |
| Adaptation of HIV-1 to HLA I. Kawashima Y, Pfafferott K, Duda A, Matthews P, Addo M, Gatanaga H, Fujiwara M, Hachiya A, Kizumi H, Kuse N, Oka S, Brumme Z, Brumme C, Brander C, Allen T, Kaslow R, Tang J, Hunter E, Allen S, Mulenga J, Branch S, Roach T, John M, Mallal S, Heckerma D, Frater J, Prendergast A, Crawford H, Leslie A, Prado J, Ndung’u T, Phillips R, Harrigan R, Walker B, Takiguchi M, and Goulder P. Nature 458: 641-645, 2009 |
| Interleukin-2 therapy in patients with HIV infection. INSIGHT-ESPRIT Study Group (Oka S as a Regional Principal Investigator). N Engl J Med 361:1548-59, 2009. |
|
| |
|
河上 裕 |
慶應義塾大学医学部 先端医科学研究所 細胞情報研究部門 所長、教授 |
| 腫瘍学・免疫学・内科学 |
| Kawakami Y, Eliyahu S, Delgado CH, Robbins PF, Rivoltini L, Topalian SL, Miki T and Rosenberg SA. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci USA. 91(9):3515-1519,1994 |
| Rosenberg SA, Yang J, Schwartzentruber D, Hwu P, Marincola F, Topalian S, Restifo N, Dudley M, Schwarz S, Spiess P, Wunderlich J, Parkhurst M, Kawakami Y, Seipp C, Einhorn J and White D. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nature Med. 4(3):321-327,1998 |
| Kudo-Saito C, Shirako H, Takeuchi T, Kawakami Y. Cancer metastasis is accelerated through immunosuppression during EMT of cancer cell. Cancer Cell. 16(3):195-206,2009 |
|
| |
|
豊島 聰 |
公益財団法人日本薬剤師研修センター 理事長 |
| レギュラトリーサイエンス、免疫学 |
| Effective global drug development strategy in consideration of ethnic factors for regulatory approval in Japan. Ichimaru K, Toyoshima S, Uyama Y. Clin Pharmacol Ther. 2010; 87(3): 362-366 |
| Use of Biomarker in Drug Development-Japanese Perspectives. Uyama Y, Ishiguro A, Nakamura H, Toyoshima S. John Wiley & Sons, Inc. 2012, 269-287 |
Constitutive turnover of Phosphorylation at Thr-412 of human p57/coronin-1 regulates the interaction with actin. Oku T. Nakano M. Kaneko Y. Ando Y. Kenmotsu H. Itoh S. Tsuiji, M., Seyama, Y., Toyoshima, S., Tsuji, T. J. Biol. Chem. 2012; 287(51): 42910-42920
|
|
| |
|
西島 正弘 |
昭和薬科大学 学長 |
| 生化学 |
Molecular machinery for non-vesicular trafficking of ceramide
K. Hanada, K. Kumagai, S. Yasuda, Y. Miura, M. Kawano, M. Fukasawa, and M. Nishijima
Nature (Article), 426, 803-809, 2003
|
A Potent Adjuvant Monophosphoryl Lipid A Triggers Various Immune Response, but Not Secretion of lL-1・ or Activation of Caspase-1
K. Okemoto, K. Kawasaki, K. Hanada, M. Miura, and M. Nishijima
J. Immunol., 176, 1203-1208, 2006
|
Structural basis for specific lipid recognition by CERT responsible for nonvesicular trafficking of ceramide
N. Kudo, K. Kumagai, N. Tomishige, T. Yamaji, S. Wakatsuki, M. Nishijima, K. Hanada, and R. Kato
Proc. Natl. Acad. Sci.USA., 105, 488-493, 2008
|
|
| |
|
早川 堯夫 |
近畿大学薬学総合研究所 所長 |
| 生物化学、薬学 |
| バイオ医薬品開発の主流を占める糖タンパク質.バイオ医薬品開発における糖鎖技術（早川堯夫、掛樋一晃、平林 淳監修）、早川堯夫、シーエムシー出版、pp.1-21（2011） |
| Human adipose tissue-derived multilineage progenitor cells exposed to oxidative stress induce neurite outgrowth in PC12 cells through p38 MAPK signaling. Moriyama M, Moriyama H, Ueda A, Nishibata Y, Okura H, Ichinose A, Matsuyama A, Hayakawa T. BMC Cell Biol. 13(1):21（2012） |
| Efficient Generation of Functional Hepatocytes From Human Embryonic Stem Cells and Induced Pluripotent Stem Cells by HNF4α Transduction. Takayama K, Inamura M, Kawabata K, Katayama K, Higuchi M, Tashiro K, Nonaka A, Sakurai F, Hayakawa T, Kusuda Furue M, Mizuguchi H. Mol Ther. 20(1) 127-137 (2012). |
|
| ○ |
|
堀田 知光 |
国立がん研究センター 理事長・総長 |
| 血液腫瘍内科 |
Phase II/III Study of R-CHOP-21 Versus R-CHOP-14 for Untreated Indolent B-Cell Non-Hodgkin’s Lymphoma: JCOG 0203 Trial
Watanabe T, Tobinai K, Shibata T, Tsukasaki K, Morishima Y, Maseki N, Kinoshita T, Suzuki T, Yamaguchi M, Ando K, Ogura M, Taniwaki M, Uike N, Takeuchi K, Nawano S, Terauchi T and Hotta T
J Clinical Oncol 29(30):3990-3998, Oct 2011
|
Phase II Study of cyclophosphamide, doxorubicin, vincristine, prednisolone (CHOP) therapy for newly diagnosed patients with low- and low-intermediate risk, aggressive non-Hodgkin’s lymphoma: final results of the japan Clinical Oncology Group Study, JCOG9508
Kagami Y, Itoh K, Tobinai K, Fukuda H, Mukai K, Chou T, Mikuni C, Kinoshita T, Fukushima N, Kiyama Y, Suzuki T, Sasaki T, Watanabe Y, Tsukasaki K, Shimoyama M, Ogura M and Hotta T
Intl J of Hematology 96:74-83, Jun 2012
|
Phase I study of BCX1777 (forodesine) in patients with relapsed or refractory peripheral T/natural killer-cell malignancies
Ogura M, Tsukasaki K, Nagai H, Uchida T, Oyama T, Suzuki T, Taguchi J, Maruyama D, Hotta T and Tobinai K
Cancer Science 103(7):1290-1295, Jul 2012
|
|
| |
|
渡邉 治雄 |
国立感染症研究所 所長 |
| 細菌学 |
| Yamamoto S, Mitobe J, Ishikawa T, Wai SN, Ohnishi M, Watanabe H, Izumiya H. Regulation of natural competence by the orphan two-component system sensor kinase ChiS involves a non-canonical transmembrane regulator in Vibrio cholerae. Mol. Microbiol. 91: 326-347. 2014 |
| Morita-Ishihara T, Miura M, Iyoda S, Izumiya H, Watanabe H, Ohnishi M, Terajima J. EspO1-2 Regulates EspM2-Mediated RhoA activity to stabilize formation of focal adhesions in enterohemorrhagic Escherichia coli-Infected host cells. PLoS One. 8(2):e55960. doi:2013 |
| Interferon-γ-producing immature myeloid cells confer protection against severe invasive group A Streptococcus infections. Takayuki Matsumura, Manabu Ato, Tadayoshi Ikebe, Makoto Ohnishi, Haruo Watanabe and Kazuo Kobayashi. Nature Communication.DOI:10.1038/ncomms1677. 2012 |
|
